Protocols for Clinical Registry Extraction and Data Submission (CREDS) IG
1.0.0-ballot - STU1 United States of America flag

This page is part of the Protocols for Clinical Registry Extraction and Data Submission (CREDS) IG (v1.0.0-ballot: STU1 Ballot 1) based on FHIR R4. . For a full list of available versions, see the Directory of published versions

: New York Heart Association OA Answer List - TTL Representation

Active as of 2023-03-29

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:ValueSet ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "NewYorkHeartAssociationAnswers"] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li>Include these codes as defined in <a href=\"http://loinc.org\"><code>http://loinc.org</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td><a href=\"https://loinc.org/LA28408-5/\">LA28408-5</a></td><td>No objective evidence of cardiovascular disease</td></tr><tr><td><a href=\"https://loinc.org/LA28409-3/\">LA28409-3</a></td><td>Objective evidence of minimal cardiovascular disease</td></tr><tr><td><a href=\"https://loinc.org/LA28410-1/\">LA28410-1</a></td><td>Objective evidence of moderately severe cardiovascular disease</td></tr><tr><td><a href=\"https://loinc.org/LA28411-9/\">LA28411-9</a></td><td>Objective evidence of severe cardiovascular disease</td></tr></table></li></ul></div>"
  ] ; # 
  fhir:url [ fhir:v "http://hl7.org/fhir/us/registry-protocols/ValueSet/NewYorkHeartAssociationAnswers"^^xsd:anyURI] ; # 
  fhir:version [ fhir:v "1.0.0-ballot"] ; # 
  fhir:name [ fhir:v "NewYorkHeartAssociationAnswers"] ; # 
  fhir:title [ fhir:v "New York Heart Association OA Answer List"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v "true"^^xsd:boolean] ; # 
  fhir:date [ fhir:v "2023-03-29T01:19:33+00:00"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "Clinical Interoperability Council"] ; # 
  fhir:contact ( [
    ( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://hl7.org/Special/committees/cic" ]     ] )
  ] [
    ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "cic@lists.hl7.org" ]     ] )
  ] [
fhir:name [ fhir:v "Clinical Interoperability Council" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://hl7.org/Special/committees/cic/index.cfm" ]     ] )
  ] [
fhir:name [ fhir:v "David Pyke" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "mailto:David.Pyke@pointclickcare.com" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "NYHA Loinc AnsWerlist"] ; # 
  fhir:jurisdiction ( [
    ( fhir:coding [
fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ;
fhir:code [ fhir:v "US" ] ;
fhir:display [ fhir:v "United States of America" ]     ] )
  ] ) ; # 
  fhir:copyright [ fhir:v "This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc"] ; # 
  fhir:compose [
    ( fhir:include [
fhir:system [ fhir:v "http://loinc.org"^^xsd:anyURI ] ;
      ( fhir:concept [
fhir:code [ fhir:v "LA28408-5" ] ;
fhir:display [ fhir:v "No objective evidence of cardiovascular disease" ]       ] [
fhir:code [ fhir:v "LA28409-3" ] ;
fhir:display [ fhir:v "Objective evidence of minimal cardiovascular disease" ]       ] [
fhir:code [ fhir:v "LA28410-1" ] ;
fhir:display [ fhir:v "Objective evidence of moderately severe cardiovascular disease" ]       ] [
fhir:code [ fhir:v "LA28411-9" ] ;
fhir:display [ fhir:v "Objective evidence of severe cardiovascular disease" ]       ] )     ] )
  ] . #